Verastem, Inc. (NASDAQ:VSTM) receives consensus PT of $14.83 from analysts

Shares of Verastem, Inc. (NASDAQ:VSTM – Get Free Report ) has been assigned an average rating of “Buy” from the six analysts that are currently covering the company, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy rating. The average 1-year target price among brokers that have issued a report on the stock in the last year is $14.83.

Several equities analysts recently issued reports on VSTM shares. Truist Financial cut their price target on Verastem from $18.00 to $15.00 and set a “buy” rating on the stock in a research report on Tuesday, August 13th. StockNews.com upgraded Verastem from a “sell” rating to a “hold” rating in a research note on Monday, August 12th. HC Wainwright decreased their target price on Verastem from $17.50 to $7.00 and set a “buy” rating on the stock in a research report on Monday, August 12th. Alliance Global Partners cut their price target on shares of Verastem from $34.00 to $20.00 and set a “buy” rating for the company in a research report on Wednesday, May 29th. Finally, B. Riley decreased their price objective on shares of Verastem from $21.00 to $7.00 and set a “buy” rating for the company in a research note on Wednesday, the 24th July.

Read our latest research report on Verastem

Institutional inputs and outputs

Several institutional investors have recently bought and sold shares of VSTM. Vanguard Group Inc. raised its stake in shares of Verastem by 0.9% in the first quarter. Vanguard Group Inc. now owns 1,160,931 shares of the biopharmaceutical company worth $13,699,000, after buying another 10,678 shares during the period. Nantahala Capital Management LLC purchased a new position in Verastem in the second quarter valued at $1,192,000. Bank of New York Mellon Corp purchased a new position in Verastem in the second quarter valued at $203,000. Rhumbline Advisers grew its position in shares of Verastem by 4,172.0% in the second quarter. Rhumbline Advisers now owns 28,793 shares of the biopharmaceutical company’s stock worth $86,000 after acquiring an additional 28,119 shares during the period. Finally, Acadian Asset Management LLC purchased a new stake in shares of Verastem during the second quarter valued at about $82,000. 88.37% of the shares are currently held by hedge funds and other institutional investors.

Verastem price performance

Shares of VSTM opened at $2.42 on Friday. Verastem has a fifty-two week low of $2.10 and a fifty-two week high of $14.22. The company has a debt-to-equity ratio of 1.88, a quick ratio of 3.28, and a current ratio of 3.28. The firm has a market cap of $97.38 million, a price-to-earnings ratio of -0.55 and a beta of 0.16. The stock’s 50-day simple moving average is $2.74 and its 200-day simple moving average is $7.14.

Verastem (NASDAQ:VSTM – Get Your Free Report ) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($1.06) by $0.75. The company had revenue of $10.00 million for the quarter. As a group, equities analysts forecast that Verastem will post -3.54 earnings per share for the current fiscal year.

About Verastem

(Get a free report

Verastem, Inc, an early-stage biopharmaceutical company, focuses on the development and commercialization of drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen kinase pathway that is involved in cell proliferation, migration, transformation and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.

Featured stories

Get news and reviews for Verastem Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Verastem and related companies with MarketBeat.com ‘s FREE daily email newsletter.